SARS-CoV-2 (COVID-19) Spike 156-157EFdel Peptide (Delta Variant)

SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent.

43740568

P0DTC2

QHD43416

Peptides

200 ug/mL

PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide

Blue Ice

Store SARS-CoV-2 (COVID-19) Spike 156-157EFdel Peptide (Delta Variant) at -20˚ C, stable for one year.

SARS-CoV-2 (COVID-19) Spike 156-157EFdel Peptide (Delta Variant) is used for blocking the activity of theSARS-CoV-2 (COVID-19) Spike 156-157EFdel Antibody (Delta Variant)

Surface glycoprotein

Severe acute respiratory syndrome coronavirus 2

Zhang et al. JAMA 2021, 325 (13) : 1324-26.

Reardon. Nature 2021.

Delphine. Nature 2021, 596 (7871) : 276-280.

SARS-CoV-2 Spike 156-157EF antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein

Blocking

SARS-CoV-2

1791269090

Liquid